Revolution Medicines publishes pancreatic cancer trial data in NEJM

May 6, 2026 6:00 PM

Revolution Medicines announced that The New England Journal of Medicine published data from its Phase 1/2 clinical trial evaluating daraxonrasib ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found